Worries over potential inaccuracies from a fast-acting COVID-19 test touted by the Trump administration has prompted the Fond du Lac Band of Lake Superior Chippewa to stop using the product, after federal regulators warned the public about it.
"After thorough research and investigation it was decided that the immediate removal of Abbott ID Now from our COVID-19 testing options was necessary, until further research has been conducted," the band announced Tuesday on Facebook. All patients who were tested with the system in the past 14 days were contacted, and additional testing may be done through the Mayo Clinic Laboratory.
Last Thursday, the U.S. Food and Drug Administration said the test, in use at more than 1,000 sites nationwide, may be returning false negative results in some cases.
Illinois-based Abbott Laboratories said its ID Now system is the most widely used point-of-care instrument in the U.S., and was one of the first systems to be granted an emergency authorization by the FDA for use to detect molecular traces of the virus that causes COVID-19. More than 2 million of the tests have been delivered nationwide.
Abbott said the system can positively detect COVID-19 in as little as five minutes, making it the fastest system on the market. The toaster-sized system is intended to be used near the patient after they have given a nasal- or throat-swab specimen. Internal testing showed the system correctly detected COVID-19 in 30 of 30 viral samples, and ruled out detection in 30 of 30 negative samples.
But the system has been criticized for its accuracy.
A comparative, non-peer-reviewed study of samples from 101 patients at New York University Langone Tisch Hospital found what the researchers characterized as "low sensitivity" and "high false negative results."
Abbott said the NYU study that prompted the FDA warning "is an outlier" and the company was reinforcing proper sample collection and handling instructions with users. "We've seen well-conducted studies with accuracy rates ranging from the mid-80s to mid-90s, which is what you'd expect from a rapid point of care test," Abbott spokesman John Koval wrote in an e-mail.